# Index


9ACG 168

*A. haemolyticus* 104
AADC, *see* aromatic amino acid decarboxylase
AAV, *see* adeno-associated virus
Abacavir (ABC) 18
ABC, *see* Abacavir
ABC export proteins 401
ABC transporters 73
ABL, *see Arthrobacter* sp. lipase
ABL proto-oncogene inhibitors 208
absolute claudication distance (ACD) 59
absorption, distribution, metabolism, excretion, and toxicity (ADMET) 206
ACD, *see* absolute claudication distance
ACE, *see* angiotensin converting enzyme
acenocoumarol 276, 280
acetyl-CoA-α-glucos-amide-*N*-acetyl-transferase 387
acetylsalicylic acid (ASA) 285, 287
acid β-glucosidase 358–359, 413
acid ceramidase 358–360, 413
acid maltase deficiency 348, 368
acid sphingomyelinase (ASM) 360–361
Acinetobacter baumannii 260
ACS, *see* acute coronary syndrome
acute coronary syndrome (ACS) 285, 287, 330
acute coronary syndromes 334
acute myeloid leukemia (AML) 127, 182, 205, 217, 231
acute promyelocytic leukemia (APL) 144, 204
acyclovir 158
AD, *see* Alzheimer's disease
adamalysin family 381
adaptive immune responses 330
adeno-associated virus 169–171, 178, 354, 366
adeno-associated virus (AAV) 169–171, 178, 354, 366
adenosine triphosphate (ATP) 47, 58, 73, 134, 202, 207–208, 218, 230, 233, 401, 406
Adenoviruses 168
ADEPT, *see* antibody-directed enzyme prodrug therapy
ADMET, *see* absorption, distribution, metabolism, excretion, and toxicity
adoptive T cell therapy (ATC) 176
ADR, *see* adverse drug reactions
adverse drug reactions (ADR) 281, 300, 302, 362
AED, *see* anti-epileptic drugs
afatinib 200, 207, 209–210, 218
AG-120 140, 145
AG-221 139–140

age-related clonal hematopoiesis (ARCH) 135
AGI-5198 138
AGI-6780 138
AITLs, *see* angioimmunoblastic T-cell lymphomas
αKG, *see* α-ketoglutarate
algasidase alpha 356, 413
algasidase beta 356
alglucosidase alfa 369–370
Alipogene tiparvovec 171
ALK, *see* anaplastic lymphocyte kinase
ALK inhibitors 233
allosteric inhibitors 208
alpha-L-iduronohydrolase 389, 399
alpha mannosidase 371–372
alpha-mannosidosis 371, 373–374
ALS, *see* amyotrophic lateral sclerosis
Alzheimer's disease (AD) 75, 102, 111–112, 352, 384
amikacin 250
9-aminocamptothecin 161–162, 168
AML, *see* acute myeloid leukemia
AmpC lactamases 262
ampicillin 254, 258
amrinone 61
amyotrophic lateral sclerosis (ALS) 363, 384, 415
anaplastic lymphocyte kinase (ALK) 233
andexanet alfa 294
angiogenesis 105, 110–112, 131, 173, 223–226, 228–229, 325, 377, 397
angiotensin converting enzyme (ACE)
  ACE inhibitors 11, 37
angioimmunoblastic T-cell lymphomas (AITLs) 128
antianginal drugs 14
antiapoptotic protein BCL2 169
antiatherogenic effects 323–324
antibacterials 28, 243–244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270
antibody conjugates 163
antibody-directed enzyme prodrug therapy (ADEPT) 162–163
antibody–enzyme fusion proteins 163
anticoagulant proteins 276
anticoagulation therapy 283–284
antidepressant drug 28
antiepileptic drugs (AED) 23
antiinflammatory cytokines 64
antimalarial drug 33
antithrombin (AT) 277, 294, 383
antithrombin III 383
antithrombotics 276, 278, 282
antitumor drug 33, 168
apheresis 177
apixaban 276, 279, 283, 287–292, 294, 297–299, 301
APL, *see* acute promyelocytic leukemia
ApoB100, *see* apolipoprotein B100
apolipoprotein B100 (ApoB100) 316, 330
apoptosis-inducing factors 166
apremilast 66, 68
ARCH, *see* age-related clonal hematopoiesis
argatroban 279–280
arginase 169, 182
arginine deiminase 181–182
argininosuccinate lyase 182
argininosuccinate synthetase-1 182
arimoclomol 363, 415
ARN19874 108
aromatic amino acid decarboxylase (AADC) 83

AADC deficiency 84–86, 91, 94–97
arsenic trioxide 144
Arthrobacter sp. lipase (ABL) 28
artificial intelligence 39–40
arylsulfatase B 368, 388, 395, 408–409
arylsulfatases 366
ASA, *see* acetylsalicylic acid
asialoglycoprotein receptor 179
ASM, *see* acid sphingomyelinase
*Aspergillus niger* AC-54 10
*Aspergillus niger* lipase 17
*Aspergillus oryzae* lipase 18
*Aspergillus terreus* AC-430 10
asthma 27, 48, 56, 63, 66, 68, 110
AT, *see* antithrombin
ATC, *see* adoptive T cell therapy
atenolol 12, 14, 37
atherogenesis 311, 327
atherogenic cascade 325
atherosclerosis 62, 75, 109–110, 323–324, 327, 329–330, 332–333, 335
atopic dermatitis 64
atorvastatin 313, 332
ATP, *see* adenosine triphosphate
ATP synthase 134, 406
ATX, *see* autotaxin
autonomic dysfunctions 85–86
autotaxin (ATX) 102, 109–110
  ATX inhibitors 110
avanafil 49, 71–72, 74
avibactam 253–254, 259–262, 264
5-azacytidine 142, 148
aztreonam 247, 257, 260, 265

B-ALL, *see* relapsed B-cell acute lymphoblastic leukemia
B-cell non-Hodgkin lymphoma (B-NHL) 176
B-NHL, *see* B-cell non-Hodgkin lymphoma
*Bacillus amyloliquefaciens* 31
*Bacillus coagulans* 11
*Bacillus laterosporus* 32
*Bacillus subtilis* 11, 40, 103
bacterial-directed enzyme prodrug therapy (BDEPT) 163, 166
BAX protein 170
BBB, *see* blood–brain barrier
BCAT1, *see* branched-chain amino acid transaminase 1
BCL-2 family proteins 174
BCL-2 inhibition 148
BCL-2 inhibitor 233
BDEPT, *see* bacterial-directed enzyme prodrug therapy
benserazide 95
benzophenanthridine alkaloid 96
bilirubin 144, 148
bladder-cancer cells 165
BLIs, *see* β-lactamase inhibitors
β-blocker 12, 37
blood–brain barrier (BBB) 94–96, 363, 366, 400, 414
boronic acid inhibitors 265
BRAF mutant 219
brain tumors 189, 405
branched-chain amino acid transaminase 1 (BCAT1) 134
brigatinib 211, 233–234
Brivaracetam 23, 25
Bruton's tyrosine kinase (BTK) inhibitor 208
*Burkolderia cepacia* lipase 11
bystander effect 165, 170

*C. pseudotuberculosis* 104
*C. ulcerans* 101, 104
CABG, *see* restenosis after coronary-artery bypass graft

CAD, *see* coronary artery disease
Caelyx® 183–184
caffeine 50, 56
CAL-A, *see Candida antarctica* lipase A
CAL-B, *see Candida antarctica* lipase B
calcium channels 69
calmodulin (CaM) binding domains 52
cAMP, *see* cyclic adenosine monophosphate
camptothecin derivatives 162
cancer 73, 102, 107, 109–113, 115–117, 119, 127–131, 133, 136, 155–156, 158–189, 199–206, 208–230, 232–234, 300, 303, 372, 377–381, 397, 401, 408
cancer cell differentiation 128
cancer microenvironments 172
cancer therapy 155–156, 158, 160, 162–189, 200
*Candida antarctica* lipase A (CAL-A) 14
*Candida antarctica* lipase B (CAL-B) 5, 23
*Candida cylindricea* lipase 17
*Candida rugosa* lipase 10, 17
canertinib 211, 219–220
captopril 11, 268
CAR, *see* chimeric antigen receptors
CAR T-cell therapy 174
carbapenemases 252, 256, 262, 264
carbapenems 247, 252–257
CarbiDOPA 95
carbon nanotubes 402
carboplatin 185
carboxypeptidase G2 164, 168
cardiac myocyte hypertrophy 324
cardiomyocyte apoptosis 328
cardiomyocyte hypertrophy 328–329
cardioprotective effects 312, 316, 323–325, 328–329, 334
cardiovascular disease 102, 111, 311, 321, 323, 334
carpal tunnel syndrome (CTS) 390
cartilaginous tumors 128
caspase-3 220
catalytic triad 5–6
cathepsin A 352–353, 394
cathepsin B 158
cathepsin K inhibitors 34, 36,
CAZy 372
CB1954 165–167, 169
CD4+ T cell activation 331
CD8+ T cells 176, 331
CD40/CD40L signaling pathway 331
CDK, *see* cyclin-dependent kinase
ceftaroline 248–250, 254, 259
ceftaroline fosamil acetate 248
ceftobiprole 249–250
Center for Drug Evaluation and Research 156
central nervous system (CNS) 84–85, 107, 115, 118, 173, 367, 373–374, 382, 386, 394, 401, 404–405, 409, 413
cephalosporinases 252, 264
cephalosporins 249, 253–254
  cefazidime 248
  cefepime 248, 250, 267
  cefotaxime 248
  ceftriaxone 248, 250
  siderophor-type 259
ceramide-1-phosphate (CIP) 104–105
ceranopril 11
cerebral vasospasm 334

cerebrosides 349–350
ceritinib 211, 233
Cerliponase alfa 413
cervical carcinoma 166, 172
cGMP, *see* cyclic guanosine monophosphate
chaperones 348, 399, 406
CHF, *see* congestive heart failure
chimeric antigen receptors (CAR) 174
  higher generations 175
ChiroCLEC™PC 21
chitotriosidase 358
chloramphenicol 28, 31
cholesterol 31, 156, 171, 311–314, 316–318, 320, 325, 332, 362, 364, 366
  biosynthesis 314, 316–317
choline 102–105, 111, 349
chondroitin sulfate (CS) 375, 381–382, 388, 396, 409
  fucosylated 382
chromosomal transmission 254
chronic lymphocytic leukemia (CLL) 176, 205, 217
chronic obstructive pulmonary disease (COPD) 48
cilomilast 55, 64, 68
cilostazol 59–62
CIMP, *see* CpG island methylator phenotype
CIP, *see* ceramide-1-phosphate
class A lactamases 254–255, 261–262
class B lactamases 257
class C lactamases 252, 255
class C β-lactamases 255
Class D lactamases 260
clavam 247
clavulanic acid 253–254, 258–259, 262
ClinicalTrials.gov 75, 218, 222, 232
CLL, *see* chronic lymphocytic leukemia
clopidogrel 285, 287, 300
*Clostridium perfringens* 406
*Clostridium sporogenes* 167
CMV, *see* cytomegalovirus
CNS, *see* central nervous system
CoA:α-glucosaminidase *N*-acetyltransferase 391
coagulation cascade 276–277
  regulation 276–277
colorectal cancer 203–204, 210–213, 216–217, 226
COMPASS study 287
conditionally replicating adenoviruses (CRA) 169, 172
  Onyx-015 172–173
congestive heart failure (CHF) 61, 285
COPD, *see* chronic obstructive pulmonary disease
coronary artery disease (CAD) 69–70, 171, 287, 312
coronary stent implantation 326
coronary vasospastic angina 323
*Corynebacterineae* 103
COX, *see* cyclooxygenase
COX-2 323
CpG island methylator phenotype (CIMP) 131
CRA, *see* conditionally replicating adenoviruses
crenolanib 211, 227, 231–232
CRISPR/Cas9 414
CRISPR technology 189
crizotinib 211, 233–234
CRS, *see* cytokine release syndrome
CS, *see* chondroitin sulfate
CTS, *see* carpal tunnel syndrome
cyclases 48, 51–52, 58, 69

cyclic adenosine monophosphate (cAMP) 47, 59
cyclic guanosine monophosphate (cGMP) 47
cyclin-dependent kinase (CDK) 327
cyclooxygenase (COX) 9
cyclophosphamide 156, 165
cysteine sulfininc acid decarboxylase 86
cytarabine 142, 147, 182
cytochrome c oxidase 134
cytochrome P450 158, 165, 282
cytokine release syndrome (CRS) 177
cytokines 64, 144, 177, 327, 331, 335, 377
cytomegalovirus (CMV) 21, 158
cytomegalovirus infections 21
cytosine deaminase 165, 168, 170, 173

D-2-hydroxyglutarate (D-2HG) 128
D-2HG, *see* D-2-hydroxyglutarate
D-2HG aciduria (D-2HGA) 132
D-2HGA, *see* D-2HG aciduria
dabigatran etexilate 276, 280, 283, 288–290, 294
dacomitinib 212, 220–223
danaparoid 278
DAPT, *see* double antiplatelet therapy
daunomycin 183–184, 186
daunorubicin 147, 161
DaunoXome® 183–184
DDC, *see* L-DOPA decarboxylase
DDC inhibitors 95
decitabine 138, 148
deep vein thrombosis 280
dementia 48, 62, 352, 401
1-deoxygalactonojirimycin (DGJ) 357
depression 48, 64–65, 84, 405
dermatan sulfate 388, 409
desirudin 279
desketoraloxifene 108, 116
DGJ, *see* 1-deoxygalactonojirimycin
diabetes type 2 73
diastolic dysfunction 328
dicoumarol 280
differentiation syndrome 143–144
diltiazem hydrochloride 17
dimercaprol 268
dioxygenases 129–131, 133
dipyridamole 59
direct factor Xa inhibitor (DXI) 276
direct oral anticoagulants (DOAC)
  clinical practice 276
  dosage 294, 298
  drug interactions 299–301
  mode of action 292–293
  pharmacodynamics 287
  pharmacokinetics 290
  Phase III clinical trials 284, 286
  therapeutic indications 285
direct thrombin inhibitor (DTI) 276
directed enzyme prodrug activation 162–163, 165, 167, 169, 171, 173, 175, 177–179, 181, 183, 185
directed evolution 39–40, 172
DMPK profile 115
DNA hypermethylation 131, 133, 138
DNA repair enzyme 131
dopamine 83–85, 93–94, 96, 185–186
  metabolic pathway 85
double antiplatelet therapy (DAPT) 300
doxorubicin 73, 159–161, 179–181, 183–184
DTI, *see* direct thrombin inhibitor

dual-cancer targeted therapies 218
Dunathan hypothesis 88, 92
DXI, *see* direct factor Xa inhibitor

Ebola 364
Ebola viruses (EboV) infection 364
  inhibitor 364
ECM, *see* extracellular matrix
ED, *see* erectile dysfunction
edoxaban 276, 279, 283, 287–292, 294–297, 300–301
EGFR, *see* epidermal growth factor receptor
EGFR inhibitors 209
  first-generation 218
  second-generation 209
Elaprase 402–403
elosulfase alfa 407–408
EMA, *see* European Medicines Agency
enalapril 11
enasidenib 139–145, 147–148
endothelial dysfunction 73, 321–322, 325, 332
endothelial NO 325, 333
endothelial NO production 325
endothelial NO synthase (eNOS) 325
eNOS, *see* endothelial NO synthase
enoximone 61
Enterobacteriaceae 253–254, 260
enterolactone 164
enzyme immobilization 4
enzyme/prodrug combinations 165, 167
enzyme replacement therapy (ERT) 347–348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 390, 392, 394, 396, 398, 400, 402, 404, 406, 412–414
epidermal growth factor receptor (EGFR) 170, 176, 200, 205, 208–210, 215, 217–223, 233
epigenetic regulation 128, 379
epigenetics 129, 131, 133
ErbB family 208, 218
erdafitinib 212, 228
erectile dysfunction 48–49, 69–70, 72, 323
erectile dysfunction (ED) 48–49, 69–70, 72, 323
erlotinib 200, 207, 209, 212, 218–222, 233
ERT, *see* enzyme replacement therapy
ESBLs, *see* extended spectrum β-lactamases
*Escherichia coli* 249, 408, 416
esophageal carcinoma 209, 228
esterases 3, 6, 11, 25, 31
ETC, *see* mitochondrial electron transport chain
European Medicines Agency (EMA) 171, 174, 200, 415
everolimus 224
evolocumab 319
exoglycosidase β-glucuronidase (GUS) 409
exostosin-1 (EXT-1) 380
extended spectrum β-lactamases (ESBLs) 250–251
extracellular matrix (ECM) 131, 163, 376

Faber 348, 360, 413
Fabry disease (FD) 348, 351, 356–357, 363, 413
Factor IXa (FIXa) 277

fasudil 323, 334
FD, *see* Fabry disease
FDA, *see* Food and Drug Administration
FGFR, *see* fibroblast growth factor receptor
Fh1A-binding domains 52
fibroblast growth factor receptor (FGFR) 205, 217, 227–228
fibrosis 63, 68
FIXa, *see* Factor IXa
FLT3, *see* Fms-like tyrosine kinase 3
5-fluoro-2 indolyl des-chlorohalopemide (FIPI) 112–114
5-fluorocytosine 165, 167, 170
fluoxetine 28–29, 37
flurbiprofen 10–11
5-flurouracil 168
Fms-like tyrosine kinase 3 (FLT3) 205, 217
fondaparinux 279, 287, 290, 292, 297
Food and Drug Administration (FDA) 37–38, 140, 156, 164, 174, 177, 182–183, 185, 200, 226, 259, 264, 279–280, 359, 405, 408, 411, 415–416
formetorol 14
formylglycine 368, 391, 402, 407, 409
FXa inhibitor 278–279

G-protein coupled receptors (GPCR) 58
GAA, *see* α-1,4-glucosidase
GABA 25–26
GAF domains 52, 68–69
GAGs, *see* glycosaminoglycans
β-galactosidase 162, 351–353, 355, 364, 394
α-galactosidase A 355–356
β-galactosylceramidase (GalC) 365
GalC, *see* β-galactosylceramidase
Galsulfase 408, 413
ganciclovir 158, 165, 170
gangliosides 348–350, 394
gangliosidosis 348, 351, 354–355, 394
gastric carcinoma 210, 215
gastroesophageal cancer 209
gastrointestinal stromal tumor (GIST) 211, 216–217, 231
Gaucher disease(GD) 348, 350, 357–359, 412
GCS, *see* glucosylceramide synthase
GD, *see* Gaucher disease
GDEPT, *see* gene-directed enzyme prodrug therapy
GEF, *see* guanine nucleotide exchange factor
gefitinib 200, 207, 209, 212, 218–221
gene-directed enzyme prodrug therapy (GDEPT) 163, 165
gene therapies 163, 171, 174, 177, 348, 416
  Kymriah 178
  Luxturna 178
  Yescarta 178
gene therapy 165, 167, 169, 171, 178, 188–189, 354–355, 366–367, 399, 403–404, 406, 414, 416
Gene-ViroTherapy strategy 173
GISSI-HF trials 327
GIST, *see* gastrointestinal stromal tumor
glioblastoma 110, 128, 182, 203–205, 212, 223, 226
glioblastoma cell lines 110
globotriaosylceramide 355–356

glucarpidase (Voraxaze) 164
α-1,4-glucosidase (GAA) 368
  recombinant 370
glucosylceramide synthase (GCS) 359
β-glucuronidase 160, 162, 164, 168, 396, 409
glucuronosyltransferase 1A1 (UGT1A1) 144
glutamate decarboxylase 86, 90
glutathione (GSH) 129, 134, 158, 160, 181
glycogen storage disease type II 348, 368
glycoprotein lysosomal storage disorders 348
glycosaminoglycan alpha-L-iduronohydrolase 389, 399
glycosaminoglycans (GAGs) 278, 375–377, 385, 398, 402
  function 376–377
  properties 376
glycosphingolipids (GSLs) 349, 366
glycosylphosphatidylinositol phospholipase D (GPI-PLD) 102, 108–109
glypicans 379
GM1 gangliosidosis 394
GM2 gangliosidoses 353
GPCR, *see* G-protein coupled receptors
GPI-PLD, *see* glycosylphosphatidylinositol phospholipase D
Gram-negative bacteria 244, 249–251, 255, 257
Gram-positive bacteria 244, 251
GSH, *see* glutathione
GSLs, *see* glycosphingolipids
GTP, *see* guanosine triphosphate
GTP-binding proteins 320
GTPase Ras 320
guanine nucleotide exchange factor (GEF) 321
guanosine triphosphate (GTP) 47
GUS, *see* exoglycosidase β-glucuronidase

*Halomonas elongata* 11
halopemide 112–117
halopemide-based inhibitors 116–117
HCC, *see* hepatocellular carcinoma
HCII, *see* thrombin inhibitor heparin cofactor II
HD, *see* Huntington's disease
HDACis, *see* histone deacetylase inhibitors
HDL-C, *see* high-density lipoprotein cholesterol
heart failure (HF) 48–49, 61, 70, 285, 323, 327, 390, 395
HEK-293 cells 108
hematologic malignancies 135, 200, 229
hematological malignancies 176
hematopoietic stem cell transplantation (HSCT) 348, 366, 400
hemostasis 58, 378, 381
heparan sulfate (HS) 278, 375, 377–379, 384, 386, 388–392, 396, 402, 404–405, 409
  degradation 384–385, 389–391, 396, 409
heparan-*N*-sulfatase 391
heparan sulfate sulfamidase 387
heparanase 384
heparin 276, 278, 293, 375, 377–378, 380, 391
heparin-induced thrombocytopenia (HIT) 278

hepatitis C 21
hepatitis C virus 21
hepatocellular carcinoma 109, 182, 203–205, 209, 217, 225, 228, 397
hepatocellular carcinoma (HCC) 109, 182, 203–205, 209, 217, 225, 228, 397
HER2 200, 203, 208, 211, 213, 218–222
HER2 inhibitors 200
HER4 203, 208, 210–211, 218, 220
herpes B 158
herpes simplex 158–159, 165, 169, 177
herpes simplex virus thymidine kinase (HSV-TK) 165, 177
herpes zoster 158
HEX, *see* hexosaminidase enzyme
β-hexosaminidase A 354–355
hexosaminidase enzyme (HEX) 353
HF, *see* heart failure
high-density lipid cholesterol 31
high-density lipoprotein cholesterol (HDL-C) 171
high sensitivity C-reactive protein (hs-CRP) 331
hirudin 279
histidine decarboxylase 86, 89–90
histone deacetylase inhibitors (HDACis) 362
histone demethylases 131
HIT, *see* heparin-induced thrombocytopenia
HIV infection 22
HMG-CoA reductase 156, 159, 313
HMG CoA reductase inhibitor 34
HMG-coenzyme A (HMG-CoA) reductase 156
homologous recombination (HR) 133
HOPS complex 364
horseradish peroxidase (HRP) 162
HR, *see* homologous recombination
HRP, *see* horseradish peroxidase
HS, *see* heparan sulfate
HS proteoglycans 378
hs-CRP, *see* high sensitivity C-reactive protein
HSCT, *see* hematopoietic stem cell transplantation
HSV-TK, *see* herpes simplex virus thymidine kinase
human β-glucuronidase 164
human PLD inhibitors
  triazaspirone-based 115
  universal 108, 115–117
human PLD1 102
human PLD2 102
Huntington's disease (HD) 352
Hurler's syndrome 373, 389, 399–400
hyaluronan synthase 398
hyaluronidase 388, 397–398
α/β hydrolase fold 5
α/β hydrolases 5
hydrolases 3, 5–7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 158, 179, 348, 358, 410
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 312
hyperbilirubinemia 143–144
hypermethylation 131–133, 138
hypertension 17, 48–49, 62, 69–70, 72, 148, 285, 323
hypokinesia 84, 86
hypomethylating agents 138, 148

ICAM-1, *see* intracellular adhesion molecule-1

idarubicin 147
*IDH* inhibition 128, 138
*IDH* inhibitors 144, 147
*IDH1*, *see* isocitrate dehydrogenase 1
*IDH1* mutants 130, 132, 140
*IDH1/2* mutations 128, 130, 135–138
  IDH mutant tumors 132, 137
  prognostic impact 135
IDH2, *see* isocitrate dehydrogenase 1
IDH2 mutants 129–130, 133, 140, 145
IDH3 128–129
idiopathic pulmonary fibrosis 63
IDUA, *see* α-L-iduronidase
IFN-γ, *see* interferon-γ
ifosfamide 165–166
IgG-SGSH fusion protein 405
IκB kinase (IKK) inhibitor 208
imiglucerase 413
imipenemase (IMP) 257
IMP, *see* imipenemase
inflammation 9, 47, 63–64, 68, 316, 329
inflammatory bowel diseases 167
inositolphosphoglycan (IPG) 108–109
INR, *see* international normalized ratio
insulator proteins 132
insulin 31, 47, 57–58, 109, 201, 205, 401, 403, 406, 413
insulin-like growth factor II (IGFII) 406
integrins 376
interferon-γ (IFN-γ) 331
intermittent claudication 48–49, 59–60
international normalized ratio (INR) 283
intracellular adhesion molecule-1 (ICAM-1) 330
intracranial hemorrhage 284
intrahepatic cholangiocarcinoma 128
intraventricular fibrosis 328
ion channels 48
ionic liquids 10
IPG, *see* inositolphosphoglycan
ipilimumab 185
irinotecan 158–159
ischemic stroke 324, 332–335
isocitrate 127, 129–130
isocitrate dehydrogenase 1 (IDH1) 127
isocitrate dehydrogenase 1 (IDH2) 127
ivosidenib 140, 145–148

KD, *see* Krabbe disease
keratan sulfate (KS) 352, 374–375, 383–384, 388, 392–394, 407
α-ketoglutarate (αKG) 127
  αKG metabolism 130
ketoprofen 10
ketorolac 10
kinases 48, 51, 58, 69, 141, 158, 165, 199–204, 206–208, 210, 212, 214, 216, 218, 220, 222–226, 228, 230, 232, 234, 320, 379
KIT inhibitors 208
*Klebsiella oxytoca* 23–24
*Klebsiella pneumonia* 255, 257
KPC carbapenemases 262
Krabbe disease (KD) 348, 365–366

KS, *see* keratan sulfate
kynurenine aminotransferase 95

L-3,4-dihydroxyphenylalanine (L-DOPA) 83, 85, 92–96
L-5HTP, *see* L-5-hydroxytryptophan
L-asparaginase 182
L-DOPA, *see* L-3,4-dihydroxyphenylalanine
L-DOPA decarboxylase (DDC) 83–97
  active site 87, 88
  apoDDC 90, 91
  catalysis 91–94
  holoDDC 90
  inhibitors 95–96
  structure 86–91
L-dopaquinone 185
α-L-iduronidase (IDUA) 401, 413
L-leukodopachrome 185
L-mevalonate 313, 320
α-L-rhamnosidase 179
L-sulfoiduronate sulfatase 387
β-lactam antibiotic 245, 250–252, 255, 264
  classes 245, 251–252
  resistances 250, 264
β-lactamase 243–244, 246–248, 250–254, 256–260, 262, 264, 266, 268, 270
  classes 246, 249, 251, 253, 259
  mode of action 244–246, 251, 253, 258, 263, 266
  structure 243, 248, 251, 253, 267–268, 270
β-lactamase inhibitors (BLIs) 243–244, 246–248, 250, 252–254, 256, 258, 260, 262, 264, 266, 268, 270
  diazabicyclooctane (DBO)-type 259
  first-generation 257
  second-generation 259, 263–264
  third-generation 264
β-lactams 243–246, 248, 250–254, 256–258, 260, 262, 264, 266, 268, 270
lactosylceramide 355
lamivudine 21, 38
lapatinib 200, 213, 218–219
laronidase 399–400, 413
LDL-C 311–312, 314, 316–319, 325, 327–328, 331–332
LEAPT, *see* lectin-directed enzyme-activated prodrug therapy
lectin 163, 178–179
lectin-directed enzyme-activated prodrug therapy (LEAPT) 163
lectin-directed glycoconjugate 179
lectins 178, 349
*Leishmania* 103–104
lepirudin 279
leukocytosis 145, 147
leukotriene B4 64
Lewy's bodies 84
lipases 3–6, 8–10, 14, 17–18, 23, 25, 27, 31, 39–41
  reaction mechanism 6–7
  selectivity 8
  solvent tolerance 6, 41
  structural features 5
  thermostability 5–6, 8
lipid rafts 366
lipid-water interface 4
lipidome 349
lipoprotein lipase (LPL) 170–171
lisinopril 11, 37
LMWH, *see* low molecular weight heparins
Lobucavir 21, 23
long noncoding RNAs 200
lovastatin 159, 313

low grade glioma 128
low molecular weight heparins (LMWH) 276
*Loxosceles* 104, 106
*Loxosceles intermedia* 106
LPC, *see* lysophosphatidylcholine
LPL, *see* lipoprotein lipase
lumican 383
lysophosphatidylcholine (LPC) 104–105, 110
lysosomal glucocerebrosidase 359
lysosomal proteins 348
lysosomal storage disorders 347–348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 390, 392, 394, 396, 398, 400, 402, 404, 406, 412–414

mAb, *see* monoclonal antibody
major histocompatibility complex class II (MHC-II) receptors 331
major histocompatibility complex (MHC) 175, 331
malignant melanomas 186
MAO-A, *see* monoamine oxidase A
MAO-B, *see* monoamine oxidase B
MAO inhibitors 96
masitinib mesylate 228
matrix metalloproteinases 158, 330, 379
MBLs, *see* metallo-β-lactamases
MDEPT, *see* melanocyte-directed enzyme prodrug therapy
MDS, *see* myelodysplastic syndromes
MEF2, *see* myocyte enhancer factor 2
melanocyte-directed enzyme prodrug therapy (MDEPT) 163, 184, 186
melanoma cells 162, 174, 187
*Melilotus officinalis* 280
mesothelin 176
MET kinase inhibitors 230
MET oncogene 228–230
metabolic reprogramming 134
metachromatic leukodystrophy 348, 364
metachromatic leukodystrophy (MLD) 348, 364
metallo-β-lactamases (MBLs) 253
  PMPC inhibitors 269
metastatic breast cancer 218, 220
metastatic differentiated thyroid cancer 226
methicillin 248, 250
methylcytosine dioxygenases TET 131
metoprolol 12
mevastatin 156
MHC, *see* major histocompatibility complex
MIC, *see* minimal inhibition concentration
microbiome 282
migalastat 357, 412
miglustat 359, 370
milrinone 61–62
minimal inhibition concentration (MIC) 249
mitochondrial electron transport chain (ETC) 134
mitogen-activated protein kinase 63, 208
mitogen-activated protein kinase phosphatase 1 (MKP-1) 63
MKP-1, *see* mitogen-activated protein kinase phosphatase 1
ML298 115, 117–119

ML299 115, 117–119
ML395 115, 118–119
MLD, *see* metachromatic leukodystrophy
MM, *see* multiple myeloma
molecular imprinting 40
monoamine oxidase A (MAO-A) 28
monoamine oxidase B (MAO-B) 28
monobactam 247, 254, 265
monoclonal antibody (mAb) 163, 200, 401, 405
moprolol 12, 14
MPN, *see* myeloproliferative neoplasms
MPS, *see* mucopolysaccharidosis
MPS I 386, 389, 399–400, 413–415
MPS II 351, 386, 389–390, 402, 413, 415
MPS III 386, 390–392, 404
MPS IV 386, 392–393
MPS IX 397
MPS syndromes
  Hunter 351, 386, 389, 399, 402, 413
  Hurler 386, 389, 400
  MPS syndromes, Hurler-Scheie 387, 389
  Maroteaux-Lamy 386, 388, 413
  Morquio 352, 394
  Sanfilippo 390, 392, 404–405
  Scheie 389, 399
  Sly 396, 409
MPS VI 386, 395, 408–409, 413
MPS VII 386, 396, 409–413
mRNA demethylase 131
MRSA, *see* mutations in the active site
MSD, *see* multiple sulfatase deficience
mTOR signaling 134
mucopolysaccharidosis (MPS) 352, 388, 392, 395–397, 402, 408, 413
*Mucor meihei* (*R. meihei*) lipase 17
multiple myeloma (MM) 159–160, 166, 212, 380
multiple sulfatase deficiency (MSD) 364, 366–367
mutations in the active site (MRSA) 251
*Mycobacterium* sp. 103
*Mycobacterium tuberculosis* 33
myelodysplastic syndromes (MDS) 135
myeloproliferative neoplasms (MPN) 135
myocardial hypertrophy 323, 327
myocardial infarction 70, 287, 317, 319, 327, 332
myocyte enhancer factor 2 (MEF2) 326
myosin light chain kinase 59
myosin light chain (MLC) phosphatase 320

*N*-acetyl-α-D-glucos-amine-6-sulfatase 387
*N*-acetyl- α-D-glucosaminidase 387, 391
*N*-acetylgalactosamine-4-sulfatase 395
*N*-acetylgalactos-amine-6-sulfatase 388
α-*N*-acetylgalactosaminidase 356
*N*-acetylglucosamine-6-sulfatase 391–392
α-*N*-acetylglucosaminidase 404, 406
*N*-acylethanolamine (NAE) 107
*N*-glucosamine 3-*O*-sulfatase 404
*N*-n-butyl-1-deoxynojirimycin 369
*N*-phenyl triazaspirone congener (NPTSC) 114

nacubactam 260
NADPH oxidase 323–324, 329
NAE, *see N*-acylethanolamine
nafcillin 249
nanocarriers 362, 414
nanomedicines 180, 188
nanoparticles 180–181, 188
NAPE–PLD 102
Naringinase, N 179
NDM-1, *see* New Delhi Metallo-β-lactamase
necrosis factor-α (TNF) 378
neonatal non-immune hydrops fetalis 396
neratinib 209, 214, 218
neuraminidase 1 394
neurodegeneration 84, 388–389, 398, 402
neurodegenerative disorders 103, 109, 405, 407
neurological disorders 110
neurometabolic disorders 394
neuromodulator 84
neurotransmitters 83–84
New Delhi Metallo-β-lactamase (NDM-1) 257
Niemann–Pick disease (NPD) 348, 359–360, 362–363, 415
nitric oxide (NO)/cGMP pathway 69
nitroreductase 165–166, 169
NOACs, *see* non-vitamin K oral anticoagulants
Nobel Prize 48–49, 244
*Nocardia* sp. 103
non-receptor tyrosine kinases (non-RTK) 201
non-small-cell lung cancer (NSCLC) 169, 209
non-statin trials 318
non-vitamin K oral anticoagulants (NOACs) 276
non-HKD-PLDs 102, 107
non-RTK, *see* non-receptor tyrosine kinases
non-steroidal anti-inflammatory drugs (NSAIDs) 9, 300
Novozym® 435 lipase 10
NPD, *see* Niemann–Pick disease
NPTSC, *see N*-phenyl triazaspirone congener
NSAIDs, *see* non-steroidal anti-inflammatory drugs
NSCLC, *see* non-small-cell lung cancer

*O*-6-alkylguanine-DNA alkyltransferase 174
3-*O*-sulfogalactosylceramide 367
oculogyric crises 86
odanacatib 34, 36
off-target effects 208, 284
olipudase alfa 362
oncogenic addiction 202
orphan disease therapies 412
ORR, *see* overall response rate
OS, *see* overall survival
Oseltamivir phosphate 18
overall response rate (ORR) 141
overall survival (OS) 136, 221, 232, 234
OXA-lactamases 262
oxapenam 247
oxidative stress 162, 328–329, 332, 335

*P. brevicompactum* 156
p53 172, 174, 328
PA, *see* phosphatidic acid
paclitaxel 73, 180, 185

pancreatic cancer 204–205, 209, 212, 233, 381
Parkinson's disease (PD) 28, 38, 83, 102, 111–112, 352
paroxetine 74
PARP, *see* poly(adenosine 5'-diphosphate-ribose) polymerase
PASS, *see* post-authorization safety studies
PBPs, *see* penicillin-binding proteins
PC, *see* phosphatidylcholine
PCC, *see* prothrombin complex concentrates
PCI, *see* percutaneous coronary intervention
PCSK9 inhibition 317, 319
PCSK9 inhibitors 319, 332
PCSK9 trials 317
PD, *see* Parkinson's disease
PD-L, *see* programmed cell death ligand
PDE, *see* phosphodiesterases
PDE inhibitors 53, 63, 72, 75
PDE-isozymes 50
PDE subfamily 52
PDE3 49–50, 56–62, 70, 74
PDE4 49–50, 55, 62–66, 68, 74
PDE4 family 62
PDE4 isoforms 62–63
PDE4-selective inhibitors 63
PDE4B 55–56, 64
PDE4D 54–56, 63–64, 68
PDE5 48–50, 53–55, 59, 68–74
PDE5-Inhibitor 49, 71, 74
PDE5 inhibitors 49, 69–70, 72–73
PDE5A 55–56, 68–69
PDE6 56, 71, 74
PDEPT, *see* polymer directed enzyme prodrug therapy
PDGF, *see* platelet-derived growth factor
PDGFR, *see* platelet-derived growth factor receptor
PE, *see* pulmonary embolism
peginterferon alfa-2b 185
PegIntron 185
pegvaliase 415
penams 247
penicillin 162, 243–246, 249–252, 266
penicillin-binding proteins (PBPs) 245, 251
  staphylococcal 249
penicillin G 162
penicillin V 252
*Penicillium chrysogenum* 246
*Penicillium citinium* 156
*Penicillium notatum* 243
peptidoglycan 244–245, 252
  biosynthesis 244
percutaneous coronary intervention (PCI) 279
peroxisome proliferator-activated receptor (PPARs) 31, 323
peroxisome proliferator-activated receptors (PPARs) agonists 31
PF-8380 110
PFS, *see* progression-free survival
pharmaceutical ingredients 1, 9
  biosynthesis
    lipase mediated 9
pharmacological chaperone 348, 355, 357, 369–370
phenprocoumon 276, 280–282
phenylalanine hydroxylase 85, 415–416
phenylketonuria (PKU) 415
phosphatase 103–104, 248, 320, 326
phosphatidic acid (PA) 63, 102–103, 106–107, 109, 111

phosphatidylcholine (PC) 102–103, 111, 183, 187
phosphatidylglicerol 187
phosphatidylinositol-3 kinase (PI3K)/Akt pathway 326
phosphodiesterases (PDE) 47–48, 50–56, 58, 60, 62–64, 66, 68, 70–72, 74–76
  available crystal structures 55
  structure 52, 56, 67
phospholipase $A_2$ ($PLA_2$) 183–184
phospholipase D (PLD) 107–108, 117, 119
phospholipases C (PLC) 183
*Photorhabdus luminescens* 168
Pictet–Spengler adduct 93–94
pitavastatin 313
PIVKA, *see* proteins induced by vitamin K absence
PKA isoforms 51
PKU, *see* phenylketonuria
$PLA_2$, *see* phospholipase $A_2$
plaque regression 329
plasmin 161
*Plasmodium falciparum* 33
platelet aggregation 57–60, 104–105, 325
platelet cytoskeleton 334
platelet-derived growth factor (PDGF) 201, 205, 217
platelet-derived growth factor receptor (PDGFR) 201, 205, 217
PLC, *see* phospholipases C
PLD, *see* phospholipase D
PLD superfamily 103, 121–122
pleiotropic effects 312, 317–320, 325, 333–335
pneumonia 250, 255, 312, 392
poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) 133
poly(lactic-co-glycolic acid) 362
polymer directed enzyme prodrug therapy (PDEPT) 163, 178, 182
polymer-drug conjugates 180
Pompe disease 348, 368–370, 413
porine proteins 250
post-authorization safety studies (PASS) 284
potassium channels 69
PPARs, *see* peroxisome proliferator-activated receptor
PR-104A 166
pravastatin 313, 317–318, 332
pregabalin 8, 25–26
procoagulant proteins 276
prodrug 18, 21–23, 155–188, 248, 280, 288–291
  activation 155–156, 158, 160–188
  different types 169, 185
  examples 156, 158–159, 163, 169
programmed cell death ligand (PD-L)
  PD-L1 229
  PD-L2 229
progression-free survival (PFS) 221
prolyl 4-hydroxylases 131
*Propionibacterineae* 103
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor 318
prostaglandin-endoperoxide synthase-2 323
prostate cancer 73, 161, 164, 169, 203–204, 214, 379, 408
prostate specific antigen (PSA) 161
protein C system 278
protein kinase G 68
protein kinases 48, 58, 69, 202, 320

proteinase-activated protein-4 277
proteins induced by vitamin K absence (PIVKA) 281
*Proteus mirabilis* 255
prothrombin complex concentrates (PCC) 294
prothrombinase complex 277
PSA, *see* prostate specific antigen
*Pseudoalteromonas haloplanctus* 357
*Pseudomonas aeruginosa* 40, 164, 250, 254, 260
*Pseudomonas cepacia* lipase 17
psoriasis 64, 68
psychosine 365–366
PTEN phosphatase 326
PTPζ/RPTPβ 382
pulmonary arterial hypertension 48–49
pulmonary embolism (PE) 280
pulmonary fibrosis 63, 68
pulmonary hypertension 49, 62, 69–70, 72, 323
Purkinje cell 382

QT prolongation 147

(*R*)-ramatroban 27
(*R*)-thiolactomycin 33–34
Rac 320, 324
RAF inhibitors 208
Ragaglitazar 31
raloxifene 116
Ras-like proteins 320
Rasagiline mesylate 28, 30
reactive oxygen species (ROS) 129, 324
real world data 284
receptor tyrosine kinase receptor/receptor tyrosine kinase-like orphan receptor 1 (ROR1) 200, 232
receptor tyrosine kinases (RTKs) 199–204, 206–208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 379
  function 201–202
  structure 201–202, 207
relapsed B-cell acute lymphoblastic leukemia (B-ALL) 176
relapsed/refractory (R/R) AML 140
relebactam 253, 260
renal cell carcinoma 209
renal insufficiency 298
restenosis after coronary-artery bypass graft (CABG) 326
revascularization 317, 319, 326
RGD peptide 189
rheumatism 110
rheumatoid arthritis 64, 312, 397
*Rhizomucor meihei* lipase 5
Rho-associated protein kinases (ROCKs) 320
Rho-binding domains 321–322
Rho GTPase subfamily 324
Rho GTPases 320, 334
Rho kinases 320–322
RhoA/ROCK pathway 323, 328
Ribavirin 21–22, 37
ripasudil 334
rivaroxaban 276, 279, 283, 287–292, 294, 297, 299–300, 302–303
ROCK inhibitors 325, 328, 331, 334
ROCKs, *see* Rho-associated protein kinases
roflumilast 55, 66, 68
rolipram 55, 63, 65–67

ROR1, *see* receptor tyrosine kinase receptor/receptor tyrosine kinase-like orphan receptor 1
ROR1 inhibitors 200, 232
ROS, *see* reactive oxygen species
rosuvastatin 34–35, 313, 316–318, 327
RTKs, *see* receptor tyrosine kinases

*S. chromofuscus* 104, 106
(*S*)-ibuprofen 9–10
(*S*)-naproxen 10
(*S*)-ranolazine 14
S02030 265, 267
Sandhoff disease 348, 354–355, 363
sarco/endoplasmic reticulum $Ca^{2+}$ ATPase (SERCA) 161
SBLs, *see* serine-β-lactamases
schizophrenia 48, 64, 74–75
scPLD 102–104
*Sebelipase alpha* 413
secondary glioblastoma 128
secondary prevention in patients in atrial fibrillation (SPAF) 280, 284–286, 294–296
selective oestrogen receptor modulators (SERMS) 116
SERCA, *see* sarco/endoplasmic reticulum $Ca^{2+}$ ATPase
serglycin 378, 381
serine-β-lactamases (SBLs) 247, 252, 254, 257, 264
serine proteases 5, 278
SERMS, *see* selective oestrogen receptor modulators
serotonin 64, 74, 83–85, 93, 300
  metabolic pathway 85
  re-uptake inhibitors 74
*Serratia marcescence* ECU1010 lipase 18
Shope papilloma virus 169
sialidases 352
signaling molecules 107, 111–112, 220, 226, 231, 376, 380
sildenafil 48–50, 55, 69–75
simvastatin 313, 317–318
SM, *see* sphingomyelin
small molecule inhibitors (SMI) 200, 206–207
smart nanoplatforms 189
SMC apoptosis 327
SMC proliferation 327, 335
SMCs, *see* smooth muscle cells
SMI, *see* small molecule inhibitors
smooth muscle cells (SMCs) 227, 321–322, 326
SOD1, *see* superoxide dismutase
SPAF, *see* secondary prevention in patients in atrial fibrillation
sphingolipid activator proteins 350
sphingolipidoses 348–349, 351, 360
sphingomyelin (SM) 104–105, 349, 360, 363
sphingosine 349, 360, 365
SRT, *see* substrate reduction therapies
*Staphylococcus aureus* 248–250
statin LDL-C lowering trials 318
statin pleiotropy 311–314, 316–324, 326, 328, 330, 332, 334
  molecular mechanism 311–335
statin therapy 316, 329
statin trials 318–319, 328
statins 34, 156, 312–313, 315–321, 323–335
  and atherosclerosis 329
  and endothelial function 325
  and ischemic stroke 332

mechanism of action 313
and the myocardium 327
and smooth muscle cells 326
and vascular inflammation 329
*Streptococcus pneumonia* 249
*Streptomyces chromofuscus* 101–102
*Streptomyces clavuligerus* 258
*Streptomyces* sp. 185
stroke 48, 62, 280, 284–285, 287, 297–298, 303, 317, 319, 324, 332–335
stroke prevention 280
substrate reduction therapies (SRT) 348
suicidal inhibition 258
sufaminase, recombinant SOBI003 405
sulfotransferase 375, 378
superoxide dismutase (SOD1) 364, 415
suramin 106
swainsonine 371–372
syndecans 379–381
α-synuclein 84

T cell 174–178, 331, 335, 381
TAA, *see* tumor-associated antigen
tadalafil 49, 55, 71–75
TAFI, *see* thrombin-activable fibrinolysis inhibitor
*Talaromyces thermophilus* 8, 25
talazoparib) 200
Taliglucerase alpha 413
Tamiflu 18, 38
tamoxifen 116
tandutinib 216, 231
targeted based cancer therapy (TBCT) 200
taxane 219
Tay–Sachs disease 348, 353–354
tazobactam 253–254, 258–259, 262
TBCT, *see* targeted based cancer therapy
TCA cycle 129
TE, *see* thromboembolism
TEAEs, *see* treatment emergent adverse events
temozolomide (TMZ) 173, 185, 187
TF-1 erythroleukemia cells 138
TFPI, *see* tissue factor TF pathway inhibitor
thapsigargin 161
theophyilline 56
*Thermomyces lanuginosus* 28, 31, 39
*Thermomyces lanuginosus* lipase 31, 39
thrombin-activable fibrinolysis inhibitor (TAFI) 277
thrombin inhibitor heparin cofactor II (HCII) 278
thromboembolic diseases 275, 297, 377
thromboembolism (TE) 275, 282, 285, 333
thrombosis 58, 280, 303
thromboxane A2 (TxA2) antagonist 27
thrombus 104, 276
ticlopidine 285
tissue factor TF pathway inhibitor (TFPI) 277
tivantinib 216, 230
TKIs, *see* tyrosine kinase inhibitors
TKs, *see* tysosine kinases
TLS, *see* tumor lysis syndrome
TMZ, *see* Temozolomide
TNF, *see* necrosis factor-α
TNFR, *see* tumor necrosis factor receptor

topoisomerase I 158, 168
trametinib 185
transactivator CIITA 331
transpeptidases 244, 249, 257
transphosphatidylation 102, 105–106, 109
trastuzumab 218
treatment emergent adverse events (TEAEs) 143
*Trichosporon laibachii* lipase 23
troponin I 61
tumor-associated antigen (TAA) 175
tumor lysis syndrome (TLS) 145, 147
tumor necrosis factor receptor (TNFR) 176
Twitcher mouse 365–366
tyrosinase 185–187
tyrosine kinase inhibitors (TKIs) 206–207, 209–211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233
  BCR/ABL-directed 220
  type I 207
  type II 208
  type III 208
  type IV 208
  type V 208
tyrosine/serine/threonine kinases 202
tyrosine kinases (TKs) 200–202, 225, 231

UGT1A1, *see* glucuronosyltransferase 1A1

vaborbactam 253–254, 264–265, 267
valacyclovirase 158
valanafusp alpha 401, 413
valproate 218
vancomycin-intermediate *S. aureus* (VISA) 250
vancomycin-resistant *S. aureus* (VRSA) 250
vardenafil 49, 55, 71–72, 74
vascular endothelial growth factor receptor (VEGFR) 201, 205, 217, 223
vascular SMCs 327, 330
VDEPT, *see* virus-directed enzyme prodrug therapy
VEGF 164, 223–226
VEGF family 223
VEGFR, *see* vascular endothelial growth factor receptor
VEGFR-TKIs 223
  cabozantinib 223
  cediranib 223
  lenvatinib 223
  pazopanib 223
  sorafenib 223
  sunitinib 223
  tivozanib 223
  vatalanib 223
Velaglucerase 359, 413
Velaglucerase Alfa 359
velmanase alfa 373
vemurafenib 185, 219
venetoclax 148, 233
Verona integron-coded MBL (VIM) 257
vestronidase alfa-vjbk 410–411
Viagra 48, 69, 75
VIM, *see* Verona integron-coded MBL
viral glycoprotein 364
virus-directed enzyme prodrug therapy (VDEPT) 163, 168
VISA, *see* vancomycin-intermediate *S. aureus*

vitamin K 276, 281–282, 294
vitamin K antagonists (VKA) 276
VKA, *see* vitamin K antagonists
VNRX-5133 265, 267
vorinostat 362
VRSA, *see* Vancomycin-resistant *S. aureus*
Vu0155056 106
Vu0359595 106
VU0364739 114–115, 118–119

warfarin 276, 280–282, 284, 298–299, 302
WHO 185, 401
Wilms' tumor 1 (WT1) 132
WT1, *see* Wilms' tumor 1

zidebactam 260
zofenopril 11

"*With a carefully selected range of topics, this book is a must-have for all of those who work in the field. Covering topics that go from rare diseases to cancer, this volume gathers the expertise of numerous researchers to clearly demonstrate that targeting enzymes for pharmaceutical purposes is not just a thing from the past. It is a flourishing field with a great future.*"

**Dr. Maria Francisca Coutinho**
**National Institute of Health Dr. Ricardo Jorge, Portugal**

"*This volume describes some important enzymes, with special focus on those related to diseases and used as therapeutic targets or for prodrug activation, as well as the small-molecule inhibitors for these disease-relevant proteins. It also covers the biocatalytic approaches for the environmentally friendly manufacture of drugs. The book will be of broad interest to pharmacologists, chemists, and biochemists in both academia and industry.*"

**Prof. Gao-Wei Zheng**
**East China University of Science and Technology, China**

This volume of *Pharmaceutical Biocatalysis* starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.

**Peter Grunwald** studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of *Catalysts*.

V775
ISBN 978-981-4877-13-8
9 789814 877138

JENNY STANFORD
PUBLISHING